Welcome to the first version of the EPND catalogue, which includes an extensive list of international cohorts across the neurodegenerative spectrum.
This catalogue has over 60 cohorts with metadata on participants, bio samples, imaging and cognitive data.
EPND aims to accelerate research in neurodegenerative diseases and is starting this effort by providing a catalogue of these cohorts in one place. Feel free to search and filter through the catalogue.
Cohort Characteristics
Scroll through the available cohorts in the table below by using the black, horizontal and vertical scroll bars.
Click on the (+) buttons in the table to expand the categories within the list.
Set the filters to find cohorts of interest based on their characteristics.
Contact cohorts of interest by clicking on the “Contact Cohort” button.
Memory Outpatient Center of the MUMC for diagnosis of memory problems. Blood and/or cerebrospinal fluid are stored in a biobank. The biobank is a collection of stored body material, which is linked to relevant data, such as medical data, cognitive test performance or the brain scan. Patients participating in the BB-ACL study are called for repeated examination after diagnosis in order to map the course over time.
The aim is and was to facilitate research into new and existing biomarkers in the broadest sense, to establish diagnostic, prognostic and theragnostic values and further insight into the pathogenesis of neurodegenerative dementias.
Longitudinal cohort study (LCS) that screened more than 2,000 participants to collect a wide range of cognitive, clinical, neuroimaging and biomarker data to help further the understanding of the early stages of Alzheimer’s disease. From these 2,000 participants, EPAD followed up with 1,225 after one year, 421 after two years and 121 after three years before funding from the Innovative Medicine Initiative (IMI) ceased.
The cohort includes people with Parkinson’s disease, atypical parkinsonism, and healthy controls, who have their state of health regularly monitored by specialists over many years. The participants donate samples of body fluids such as blood or urine. They also take part in clinical examinations that analyse movement sequences and test their attention, memory, vision, speech, and sense of smell.
Prospective, longitudinal study that has recruited patients with early idiopathic Parkinson’s Disease, healthy controls and participants at risk of PD, and also participants with REM Sleep Behaviour Disorder.
Deutsches Zentrum Für Neurodegenelative Erkrankungen (DZNE)
Cohort on Degeneration Controls and Relatives: (1) Relatives of neurologically affected patients with e.g. AD, PD, FTD, PSP; (2) Interested persons without diagnosis of a neurodegenerative disease; (3) Persons undergoing medical treatment with other complaints in one of the clinics. Data collected yearly: medical history; neuropsychological assessment (memory, concentration and mood); neurological examination; blood sample. Optionally: further examinations of cognitive performance; motor skills; MRI; interview to a close person.
Deutsches Zentrum Für Neurodegenelative Erkrankungen (DZNE)
DELCODE included a total of 1,000 participants, examined yearly. The group includes persons with no complaints (healthy control subjects), patients with slight memory impairment or mild dementia and first-degree relatives of patients with diagnosed Alzheimer’s disease. minimum age at enrollment was 60. Data collected: comprehensive interview, detailed neuropsychological examination, blood test and a cranial MRI scan; optionally, a lumbar puncture.
Deutsches Zentrum Für Neurodegenelative Erkrankungen (DZNE)
The aim of the DESCRIBE study is to use the results obtained in the context of normal patient care, together with the results of studies on biomaterials (blood, nerve water, lacrimal fluid and urine) including genetic tests, for scientific purposes and thus to increase knowledge of neuro-degenerative diseases.
Deutsches Zentrum Für Neurodegenelative Erkrankungen (DZNE)
Longitudinal study where a total of 400 participants with and without Parkinson’s disease are being studied, with both groups of people with and without GBA mutation. The inclusion age is between 40 and 90 years.
COSCODE is an observational, longitudinal (4 years), prospective clinical cohort study involving 120 SCD, and 80 control study participants (40 individuals with no cognitive impairment, and 40 living with mild cognitive impairment - MCI, or dementia due to AD), all of which will undergo diffusion magnetic resonance imaging (MRI) and functional magnetic resonance imaging (fMRI) as well as behavioral and biomarker assessments at baseline and after 1 and 2 years.
Observational, longitudinal, population-based cohort aimed at assessing (i) diagnostic markers and risk factors for amyloid pathology in both congitively normal subjects and in normal subjects with amyloid pathology; (ii) the concordance of amyloid and other AD markers in monozygotic twins, (iii) the overlap between amyloid pathology in CSF and on PET scan. Collection of normative data for cognitive markers and biomakers for use in clinical practice.
The EMIF-AD 90+ study aimed to identify factors associated with resilience to cognitive impairment in the oldest-old. The study was conducted at the Amsterdam University Medical Center (Netherlands) and at the University of Manchester (UK). At baseline, neuropsychological and clinical data (vascular comorbidities, mood, sleep, physical performance, genetic factors) were collected from 129 participants (n=84 with normal cognition and n=38 with cognitive deficits). Regarding imaging measures: baseline MRI, Amyloid-PET and MEG have been collected. The study was part of the Innovative Medicine Initiative (IMI) European Medical Information Framework for AD (EMIF-AD) project.
Pieter Jelle Visser
Single-site
The Netherlands, The United Kingdom
2018
Yes
40
60
0
0
0
0
0
0
0
0
0
0
0
Yes
Yes
Yes
Yes
No
No
No
Yes
Yes
No
No
Yes
Yes
No
ENLIST-UK
King’s College London
The ENLIST-UK study is a 3-year longitudinal observational study aiming to recruit people with a diagnosis of dementia with Lewy bodies, Parkinson’s disease dementia or Alzheimer’s disease (for comparison purposes). Over the duration of the study, participants are invited to complete 5 visits (Screening, Baseline, Year 1, Year 2, Year 3). They are asked to complete neuropsychiatric questionnaires, undergo a blood test for biomarkers, and are also offered the option of a lumbar puncture to collect cerebrospinal fluid. The main objective is to examine if the presence of clinical core features, pro inflammatory cytokines or CSF AD markers are associated with increased rate of cognitive decline. A secondary objective is to build up a large cohort of people with dementia with Lewy bodies in the UK, collecting biological samples and longitudinal clinical and cognitive data.
17-B: Norwegian part of the prospective European DLB consortium study (E-DLB). Includes longitudinal and clinical and biomarker data, such as imaging (MRI, FDG PET and DAT SPECT), EEG, blood and CSF data.
Norwegian part of the prospective European DLB consortium study (E-DLB). Includes longitudinal and clinical and biomarker data, such as imaging (MRI, FDG PET and DAT SPECT), EEG, blood and CSF data. Not all included participants have consented to collect CSF.
The Maastricht Study, an observational prospective population-based cohort study that is characterised by a deep phenotyping approach. It studies common non-communicable diseases like type 2 diabetes, cardiovascular disease, cognitive decline, depression, and gastrointestinal, respiratory and musculoskeletal diseases.
Prospective cohort study of older adults in the Netherlands (55–84 years). The focus is on the determinants, trajectories and consequences of physical, cognitive, emotional and social functioning.
Martijn Huisman
Single-site
The Netherlands
1992
Yes
5000
0
0
0
0
0
0
0
0
0
0
0
0
No
Yes
Yes
Yes
No
No
No
No
No
No
No
No
Yes
No
Tübingen Parkinson’s Cohort (Tuepac)
University of Tübingen
Since 2005 PD patients have been recruited from the outpatient clinic and/or ward for Parkinson’s disease at the University Hospital of Tuebingen. Clinical assessments are performed and biomaterial is collected, for a subset of patients longitudinally.
The occurrence of specific symptoms that allow the clinical diagnosis of Parkinson’s and Alzheimer’s disease is preceded by a long prodromal phase in which the neurodegenerative process leads to substantial neuronal loss. To enable earlier intervention or even neuroprotective therapy it is essential to identify, characterize and validate risk and prodromal markers for Parkinson’s and Alzheimer’s disease.
The PROPARK cohort study includes over 1250 PD patients who have been examined annually and followed for 3 years (i.e., six assessments) on a broad range of motor and non-motor features.
Population-representative cohort of patients with incident Parkinson’s disease, recruited in Cambridgeshire, UK, over a 2 year period (2000-2002), and followed longitudinally for up to 20 years.
Clinical Ageing Research Unit Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University
Aims to accurately characterise two independent cohorts of incident parkinsonism in Newcastle-Gateshead and Cambridgeshire. A key objective is to identify patients who develop Parkinson’s with dementia and the factors that predict its evolution.
Community-based cohort of incident Parkinson’s disease patients, recruited in Cambridgeshire, UK, over a 5 year period (2008-2013), and followed longitudinally with repeat assessments every 18 months.
Caroline Williams-Gray/Roger Barker
Single-site
United Kindom
2008
Yes
0
0
280
0
0
0
0
0
0
0
0
0
0
No
Yes
Yes
Yes
No
No
No
No
No
No
No
No
Yes
No
LEU_DEM
KU Leuven
Cross-sectional collection of serum, plasma, DNA in a memory-recruited cohort of patients with a diagnosis of AD, DLBD, CAA, PCA or FTLD.
Rik Vandenberghe
Single-site
Belgium
2006
Yes
495
237
0
0
20
5
69
0
38
10
0
0
0
No
Yes
Yes
Yes
No
No
No
Yes
No
No
No
No
No
Yes
Alzheimer’s Research Centre KU Leuven (ARCK)
KU Leuven
A longitudinal observational memory recruited cohort study.
Rik Vandenberghe
Single-site
Belgium
2018
Yes
129
302
0
0
1
4
0
0
0
3
0
0
0
No
Yes
Yes
Yes
No
No
No
Yes
No
No
No
No
Yes
No
Flemish Prevent Alzheimer’s Disease Cohort KU Leuven (F-PACK)
KU Leuven
Community-recruited cognitively intact older adults belonging to the Flemish Prevent Alzheimer’s Disease Cohort KU Leuven (F-PACK) longitudinal observational cohort underwent a baseline evaluation consisting of detailed cognitive assessment, structural MRI and 18F-flutemetamol PET. At inclusion, subjects were stratified based on Apolipoprotein E (APOE)4 and Brain-Derived Neurotrophic Factor (BDNF) val66met polymorphism.
Rik Vandenberghe
Single-site
Belgium
2009
Yes
223
10
0
0
0
0
0
0
0
0
0
0
0
No
Yes
Yes
Yes
No
No
Yes
Yes
Yes
No
No
No
Yes
No
UCL-2016-121 (The Human Tau Project)
Cliniques Universitaires Saint-Luc, Louvain
Clinically impaired and clinically unimpaired (CU) participants recruited at the Memory Clinic and undergoing:
- MK6240 tau PET imaging
- either CSF (MCI/AD) or amyloid PET imaging (CU)
- MRI, neuropsychological examination
- APOE genotyping
- plasma sampling
Prospective multicentre cohort study on risk and protective factors for dementia in the Czech Republic.
Jakub Hort
Multi-site
Czech Republic
2011
Yes
92
324
15
0
40
0
80
10
12
10
10
0
0
Yes
Yes
Yes
Yes
No
No
No
Yes
Yes
No
Yes
Yes
Yes
No
The Memory Clinic (TMC)
UMC Berlin Charite
The Charite memory cohort comprises patients from two interdependent local memory clinics in Berlin. Patients were recruited in special memory consultation hours using modern diagnostic methods to determine whether symptoms result from a brain disease or other medical or environmental causes. Our diagnostic procedures entail cognitive, neuropsychological and physical tests in conjunction with CSF biomarkers and structural MRI data.
Oliver Peters
Multi-site
Germany
2008
Yes
176
1686
28
0
28
0
112
0
0
0
0
0
0
Yes
Yes
Yes
No
No
Yes
No
Yes
Yes
No
No
Yes
Yes
No
German Dementia Competence Network (DCN)
University of Erlangen
A cohort from German academic memory clinics. The analysis of this cohort has three major aims: (1) To facilitate the development of diagnostic tools including neuropsychology, biomarkers, imaging and genetics. (2) To implement clinical trials in mild cognitive impairment and dementia and (3) to improve standard care for dementia in Germany.
Biofluid samples from patients who have undergone diagnostic assesment at the Memory Clinic, Rigshospitalet.
Gunhild Waldemar
Multi-site
Denmark
2008
Yes
200
1100
30
0
205
10
175
15
25
25
5
300
50
Yes
Yes
Yes
No
No
No
No
Yes
Yes
No
No
Yes
No
No
Memory clinic FACE (FACE)
Fundacio ACE, Barcelona
Ace Alzheimer Center Barcelona (Fundació ACE) is a center with extensive experience in the early detection of Alzheimer’s disease. Moreover, it is a reference center of clinical trials and has its own genetics laboratory and neuroimaging analysis and processing. Its cohort possess clinical data of SCD, MCI and AD dementia patients, among other dementias, since 1996. Moreover, a DNA bank for genetic studies, with more than 18,000 cryopreserved samples, and more than 1,500 CSF/plasma paired samples, stored at -80°C and -20°C, respectively. In addition, Proteomics data from 1300 CSF/plasma paired samples (7,000 proteins: Somalogic’s SomaScan® technology / 3,000 proteins: Olink® proteomics’ Explore panel), Proteomic data in plasma exosomes of an early onset MCI cohort, clinical data, GWAS, exome, epigenomic, MRI, APOE genotyping, and metabolomic data are available.
Study aimed at widening our knowledge of neurodegenerative diseases such as Alzheimer’s disease, Lewy body dementia and frontotemporal lobe degeneration, through the study of biochemical and neuroimaging markers.
Institute of Memory and Alzheimer’s Disease, Department of Neurology, Pitié-Salpêtrière Hospital, Paris
Study aimed at verifying the clinical utility of multiplex mass spectrometry assay using CSF from highly phenotyped individuals with AD and related disorders (Socrates).
Richard Levy
Single-site
France
2017
Yes
0
234
0
0
28
0
48
0
3
7
0
0
0
Yes
No
Yes
No
No
No
No
Yes
No
No
No
No
Yes
No
BioCogBank
Paris Lariboisiere University Hospital - Université de Paris Cité, Paris
Cohort of patients suffering from cognitive decline. The cohort is based to daily clinical practice. Our aim is to discover and validate biomarker (clinical, biological, EEG and TEP and Brain MRI biomarkers). We are now working on the real world evidence of the utility of new biomarkers.
The objective of the study is to address research questions concerning the preclinical and prodromal stage of Alzheimer’s disease, more specifically to address pathways of disease development, providing evidence to the biological mechanisms that may explain observed relationships.
IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia
ARWIBO is a cross-sectional dataset including data from more than 2,600 patients enrolled in Brescia and nearby areas. The database contains data of healthy elderly Controls (CTR), individuals with Mild Cognitive Impairment (MCI), and patients with Alzheimer’s disease (AD). Images are both structural images weighted in T1 and T2 (at 1.0T or 1.5T) as well as a few PET scans.
Michela Pievani, Giovanni Frisoni
Single-site
Italy
2001
Yes
641
600
0
0
0
0
0
0
0
0
0
0
0
Yes
Yes
Yes
No
No
No
No
Yes
No
No
No
Yes
No
No
European Alzheimer’s Disease Consortium PET (EADC-PET)
GENOA EADC CENTER
PET studies as part of the European Alzheimer Disease Consortium
A multicenter prospective longitudinal cohort study on cerebral amyloid angiopathy (CAA) and spontaneous amyloid-related imaging abnormalities (sARIA) of patients with CAA-related inflammation.
Piazza Fabrizio
Multi-country
Italy
2014
Yes
0
0
0
0
0
600
0
0
0
0
0
0
0
Yes
Yes
Yes
Yes
No
No
No
Yes
Yes
No
No
No
Yes
No
Geriatric Cognitive Evaluation (GERICO 3.0)
University of Perugia
GERICO 3.0 includes clinical data from Center for Cognitive Disorders and Dementia (CDCD) by the Geriatrics and Gerontology section of the University of Perugia (Italy):
• Demographic
• Physiological history
• Patient’s medical history based on ICD-10 diagnostic criteria
• Pharmacological history according to ATC codes
• Both routine and more specialized laboratory tests
• neuroimaging
• Neuropsychological tests
• Physical performance test and anthropometric data
• Caregiver details;
• Diagnosis
Patrizia Mecocci
Single-site
Italy
2016
Yes
406
626
4
0
12
0
30
0
0
0
0
0
0
No
Yes
Yes
Yes
No
No
No
Yes
No
No
No
No
Yes
No
Memory Clinic Coimbra (Dementia Coimbra Center)
Centro Hospitalar e Universitario de Coimbra
Neurodegenerative dementia.
Isabel Santana
Single-site
Portugal
2000
Yes
100
550
0
20
30
5
5
5
5
No
No
No
Yes
No
No
No
No
No
No
No
No
Yes
No
Beyond Beta Amyloid - Deciphering Early Pathogenic Changes in Alzheimer’s disease (BBA)
Faculty of Medicine, University of Lisbon
Participants were recruited at the Lisbon memory clinic.
Longitudinal, in-depth phenotyping of patients with different forms and degrees of cognitive impairment using neuropsychological, neuroimaging, and neurochemical tools. More specifically we investigate similairities and differences between subcortical small vessel disease, Alzheimer’s disease (AD) and mixed AD/SSSV using cognitive measures, biochemical markers and magetic resonance manifestations.
Observational memory clinic cohort including data and biosamples from patients remitted to the two Memory Clinics in Karolinska University Hospital in Stockholm. The cohort is suitable for biomarker research and clinical research about dementia. CSF, serum, plasma and for a subset also whole blood are banked. Database includes eg clinical measures, memory tests, ApoE, MRI.
Population-based, multidisciplinary, collaborative study designed to estimate the prevalence and incidence of AD, other dementias, mild cognitive impairment, and other neuropsychiatric conditions of aging in the Greek population and to investigate associations between nutrition and cognitive dysfunction/age-related neuropsychiatric diseases in this Mediterranean population.
Prospective population-based cohort study on risk factors and determinants of chronic diseases in middle-aged and elderly persons, that started in 1990.
National Institute for Public Health and the Environment (RIVM), Bilthoven
Prospective, population based, longitudinal study on lifestyle and other determinants of health and disease as they develop over the life course. Started in 1987-1991, participants are examined every five years. 8th round of examination will start 2023.
Monique Verschuren
Single-site
The Netherlands
1987
Yes
3000
0
0
0
0
0
0
0
0
0
0
0
0
No
Yes
Yes
Yes
No
Yes
No
No
No
No
No
No
Yes
No
Primary care based-cohort (pcb-cohort)
University of Aveiro
Cross-sectional population-based survey of patients attending primary care health centers in the Aveiro region.
CHARIOT is a community-based register of individuals, over age 50 and without dementia, recruited from surgeries of General Practitioners in the London area. Participants undergo a series of neuropsychological evaluations to characterize the patterns of cognitive change and their inter-relationship in the earliest stages of cognitive impairment. In addition, how changes relate to the clinical presentation of cognitive impairment of the Alzheimer’s type may be evaluated over time. The study is a prospective single centre cohort study of approximately 700 participants self-referred or recruited from the CHARIOT register who were followed up for approximately 3 years (PMID: 31686098). The goals of the investigation are to better understand the natural history of cognitive and functional changes in participants at risk for MCI-AD, as well as develop a well-characterized, longitudinally followed prospective readiness cohort for future early AD clinical trials.
Non-profit organization that collects human brain tissue of donors with a variety of neurological and psychiatric disorders, but also of non-diseased donors.
The SMART-MR (Second MAnifestation of ARTerial disease-Magnetic Resonance) study is a single-center prospective cohort study among individuals with vascular disease referred to the University Medical Center (UMC) Utrecht, the Netherlands. The SMART-MR cohort forms a unique population of independently living individuals with symptomatic atherosclerotic disease and aims at investigating risk factors and consequences of brain changes on MRI and changes in cognition.
Mirjam I. Geerlings
Single-site
The Netherlands
2001
Yes
1309
0
0
0
0
0
0
0
0
0
0
0
0
No
Yes
Yes
Yes
Yes
Yes
No
Yes
No
No
No
No
Yes
No
Turkish MC Network (TRNDN)
Izmir University of Economics
Dementia and Movement Disorders Clinic patients in Medical School Hospitals of Izmir University of Economics, Dokuz Eylül University, and Istanbul University.
Gorsev Yener
Multi-site
Turkey
2015
Yes
346
440
271
5
50
0
97
0
0
10
0
3
0
Yes
Yes
No
No
No
No
No
Yes
No
No
No
Yes
Yes
No
Memory Clinic Medical University Innsbruck (Dementia Clinic MUI )
Medical University Innsbruck
A cohort of patients with neurodegenerative diseases.
French network of PD centers with collection of clinical, biological and imaging data.
Jean-Christophe Corvol
Multi-site
France
2016
Yes
0
0
27000
0
600
0
0
0
1200
400
1000
0
0
No
No
Yes
Yes
No
No
No
No
No
No
No
No
Yes
No
Pavia cohort on Parkinson’s Disease (PDGen)
University of Pavia
Cohort whose numbers are expected to rise significantly over the next year (more than 1000 participants are expected). Serum, plasma and CSF are banked, usually in relation to specific projects.
Longitudinal, multicenter cohort recruited by the multisite French National Reference Center for Early-Onset Dementia in the cities of Lille, Rouen, and Paris. The main objective of the CoMAJ study is to better understand the course of AD in young patients by providing multimodal data (i.e., clinical, biological, social, genetic, imaging, and neuropathological data). Inclusion criteria are onset before the age of 60 (although age at inclusion could be over 60), and a diagnosis of AD based on the International Working Group criteria (with abnormalities of CSF biomarkers) and compatible with those of the NIA/AA.
Florence Pasquier
Multi-site
France
2009
Yes
0
180
0
0
0
0
0
0
0
0
0
0
0
No
No
Yes
Yes
No
No
No
Yes
No
No
No
No
Yes
No
Young Onset Dementia network (YOD)
Lille Memory Clinic
Biological collection for young onset dementia and late onset dementia.
Identification of clinical, imaging and biologic markers of PD onset and progression for use in clinical trials of disease-modifying therapies.
Jean-Christophe Corvol
Single-site
France
2016
Yes
70
0
170
59
0
0
0
0
0
0
0
0
0
Yes
Yes
Yes
Yes
No
No
No
Yes
No
No
No
No
Yes
No
Brains for Dementia Research (BDR)
Newcastle University
Brains for Dementia Research is an initiative funded jointly by Alzheimer’s Society and Alzheimer’s Research UK to support brain donation and provide much-needed brain tissue for researchers.
Alan Thomas
Multi-site
The United Kingdom
2016
Yes
2179
872
0
0
0
0
0
0
0
0
0
0
0
Yes
No
No
No
No
No
No
No
No
No
No
No
Yes
Yes
BioFINDER Pilot AD cohort (BF-PilotAD)
Memory Clinic, Skåne University Hospital, Region Skåne, Sweden
Appr. 50 controls and 50 patients with prodromal AD/AD dementia, who have undergone blood sampling, CSF sampling, tau-PET imaging, MRI and cognitive testing.
Available samples: EDTA plasma, LiHeparin plasma, serum, CSF.
Oskar Hansson
Single-site
Sweden
2020
Yes
50
50
0
0
0
0
0
0
0
0
0
0
0
Yes
Yes
Yes
No
No
No
No
Yes
Yes
Yes
No
Yes
No
Yes
Southern Taiwan Elderly Health Cohort Study (STEHC)
National Cheng Kung University and National Cheng Kung University Hospital
STEHC is a nested cohort study, approximating 300 elderly patients enrolled in southern Taiwan. The database contains the questionnaire (lifestyle, diet pattern) and bio-sample of healthy elderly control and patients with Alzheimer’s disease (AD). Available samples: plasma, serum, saliva, urine.
Clininical cohort containing CSF, serum, DNA and RNA of patients with neurological complaints, sampled at time of first admission or consultation. Patients have been followed up clinically.
PPMI is a landmark study collaborating with partners around the world to create a robust open-access data set and biosample library to speed scientific breakthroughs and new treatments.
In 2010, The Michael J. Fox Foundation and a core group of academic scientists and industry partners launched the Parkinson’s Progression Markers Initiative (PPMI) toward critically needed biological markers of Parkinson’s onset and progression. PPMI has since engaged thousands of partners — more sites; scientists and clinicians; industry experts; philanthropic partners; and, most importantly, study volunteers — to build a cornerstone of Parkinson’s research. Analysis from its open-access data set and available biosample library has deepened understanding of disease and informed design of dozens of therapeutic trials.
Ten years after it began, PPMI announced a seismic expansion to nearly triple enrollment in the clinic and to add online data capture for tens of thousands. PPMI is continuing its mission to profile biological and clinical changes across the spectrum of disease with an emphasis on signals in at-risk individuals to identify the disease and intervention points as early as possible.
Fox Insight is a dynamic online longitudinal clinical study of people both with and without Parkinson's disease. The study seeks to enroll tens of thousands of diverse participants, making Fox Insight the largest and most representative Parkinson's research study to date. The Fox Insight platform deploys a variety of health, lifestyle, and Parkinson's routine assessments. Fox Insight is sponsored by The Michael J. Fox Foundation for Parkinson's Research.
Carlie Tanner, MD
Multi-country
2017
Yes
15993
16
38453
0
0
0
0
0
0
0
0
0
0
No
No
No
Yes
No
No
Yes
No
No
No
No
Yes
Yes
No
Do you have a cohort that you would like to add to our Cohort Catalogue?
If so, please click here to register with EPND and access the onboarding form.